FUDANZHANGJIANG (01349) announced that as of the disclosure date of this announcement, shareholder Mr. Wang Haibo holds 51.8286 million shares of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (hereinafter referred to as "the Company" or "FUDANZHANGJIANG"), representing 5.00% of the company's total share capital. The shares held by Mr. Wang Haibo were acquired before the company's initial public offering, and these shares were fully released from trading restrictions and listed for circulation starting June 19, 2023. The company recently received a "Notice Letter Regarding the Plan to Reduce Holdings of FUDANZHANGJIANG Shares" from Mr. Wang Haibo. Due to personal funding requirements, Mr. Wang Haibo plans to reduce his holdings of company shares by no more than 100,000 shares through centralized bidding within 3 months after 15 trading days from the disclosure date of this announcement. The planned reduction ratio will not exceed 0.01% of the company's total share capital.